Clinical Trials Directory

Trials / Completed

CompletedNCT04680182

Early Complications After Axillary and Inguinal Lymph Node Dissection in Stage III Melanoma Patients

Axillary and Inguinal Lymph Node Dissection in Stage III Melanoma Patients: A Prospective Randomized Trial of Two Approaches to Wound Drainage

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
104 (actual)
Sponsor
Oslo University Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This prospective randomized non-inferiority study is designed to compare the rate and severity of complications after axillary and inguinal lymph node dissection in stage III melanoma patients in a study group where the drain is left in place for three weeks and a control group consisting of patients managed according to the standard institutional protocol. Furthermore, variables associated with complications will be examined.

Detailed description

Consecutive stage III melanoma patients 18 years or older referred to our institution for axillary or inguinal lymph node dissection is eligible for inclusion of the study. A bipolar vessel sealing device (LigaSure, Covidien) will be used for dissection in all procedures. All patients will be scheduled for an outpatient visit with an experienced nurse three weeks after the surgery. Any deviation from the normal postoperative course will be recorded in the electronic patient journal. Complications are graded according to the Clavien-Dindo classification. Patients with complications or with suspected complications at the three-week follow up will be scheduled for new an outpatient visit. Patient demographics, clinicopathological characteristics of the primary melanoma, indication for the procedure, length of postoperative stay and early complications and treatment for complications will be collected for analysis

Conditions

Interventions

TypeNameDescription
PROCEDURESuction drainSuction drain either kept for three weeks or gradually pulled out.

Timeline

Start date
2018-05-11
Primary completion
2021-04-06
Completion
2022-09-01
First posted
2020-12-22
Last updated
2022-09-02

Locations

1 site across 1 country: Norway

Source: ClinicalTrials.gov record NCT04680182. Inclusion in this directory is not an endorsement.